Pfizer’s chief financial officer Dave Denton will soon wave goodbye to the world of pharma, pivoting back to the consumer goods industry four years after he joined the ranks of the New York drugmaker in the wake of its COVID-19 windfall.
Denton is due to pass the baton on August 15, Pfizer announced Thursday. The CFO will take up a “professional opportunity outside of the pharmaceutical industry in consumer goods,” leaving SVP of finance at Pfizer’s global biopharmaceutical business, Cecile Guegan, to take up the finance chief position in an interim basis. Pfizer noted that it's also kicking off an internal and external search for a permanent successor to the post.
CEO Albert Bourla called Denton a “a steady and trusted steward of Pfizer’s financial health,” pointing to his leadership during “some of the most important business transactions in our recent history,” including the acquisitions of Seagen, Biohaven and Metsera, which will “serve Pfizer well for years to come.”
“We wish him the very best as he returns to the consumer goods industry,” Bourla said in a company release.
As for Denton, the outgoing CFO noted that “it has been an honor and privilege to work alongside Albert for Pfizer, an iconic and purpose-driven company, during such a meaningful time in its history,” adding that Pfizer is “in excellent hands.”
His temporary replacement Guegan holds two decades of Pfizer experience and was also credited in the release with integrating Seagen into the larger company in 2024.
Pfizer’s shares slipped 3.5% Thursday morning amid news of Denton’s departure.
Denton’s career was rooted in the consumer goods segment before Pfizer, with the exec having served as CVS Health’s CFO for nearly 20 years before a 3-year stint in the same role at Lowe’s. Upon his appointment at Pfizer, he was credited with playing a “pivotal role” in CVS’s transformation to a healthcare-focused pharmacy by merging with Caremark.
He came to Pfizer with big shoes to fill in May 2022, taking over from 15-year CFO Frank D’Amelio, who had tendered his retirement. At the time of D’Amelio’s 2021 departure, the company had reaped more than $24 billion from its COVID-19 shot Comirnaty, leaving Denton with the task of utilizing the company’s new stream of major cash.
It only took one week after Denton officially started in the role for his dealmaking legacy at Pfizer to take shape through the company’s $11.6 billion acquisition of migraine partner Biohaven Pharmaceuticals, which gave the company full access to migraine med Nurtec and a wide CGRP portfolio.
The biggest deal under Denton’s leadership would come the following year with Pfizer’s $43 billion buyout of antibody-drug conjugate (ADC) drugmaker Seagen, which allowed Pfizer to slot key oncology meds Padcev, Adcetris and others into its commercial and R&D portfolios.
Pfizer’s most recent M&A flex, meanwhile, came in the form of its $10 billion Metsera buy in 2025, which ended a public brawl with Novo Nordisk over the obesity buyout target. Pfizer's commitment to winning the deal reflected renewed efforts by the company to make an obesity R&D push. Denton’s award for his work over the year earned clocked in at $9.6 million in 2025 compensation, up from his 2024 pay package of $8.1 million.
After the high peaks of its COVID-related revenues, Pfizer, and Denton, have spent the last year navigating and preparing for more lows to come.
The company forecasts 2026 revenues will land between $59.5 billion to $62.5 billion, which would come below the $62.6 billion it picked up in 2025, highlighting the impact of lower COVID sales, patent cliffs and shifting U.S. drug pricing policies.
To trim expenses, Pfizer is undergoing a sweeping cost-realignment program that aims to deliver up to $7.7 billion in net cost savings through 2027.